TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU
TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU
TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU 性质
储存条件 | Desiccate at -20°C |
---|---|
形态 | 固体 |
颜色 | 白色至米白色 |
水溶解性 | Soluble to 1 mg/ml in sterile water |
TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU 用途与合成方法
NPW-23 increases the I Ca,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7. NPW-23 increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC.
NPW-23 increases pressure-induced vasotone of the rat mesenteric arteries. Importantly, the expression of NPW is decreased in the hypertensive rats. NPW-23 (0.3 nmol, 1.0 nmol, and 3.0 nmol) induces significant increases in mean arterial pressure (MAP) in conscious, freely moving male rats. Rats that receive either 1.0 or 3.0 nmol NPW-23 demonstrate a significant increase in total activity, ambulatory activity, and duration of stereotypy. NPW-23 fails to elevate MAP in rats pretreated with phentolamine. NPW-23-induced increases in total activity, ambulatory activity, and duration of stereotypy are reduced significantly by pretreatment with the orexin type 1 receptor (OX1R) antagonist, SB-408124.
TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-P1035 | TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU | 383415-79-0 | 1mg | 1500 |
2024-11-08 | HY-P1035 | TRP-TYR-LYS-HIS-VAL-ALA-SER-PRO-ARG-TYR-HIS-THR-VAL-GLY-ARG-ALA-ALA-GLY-LEU-LEU-MET-GLY-LEU | 383415-79-0 | 5mg | 4500 |